PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: A multi-institutional analysis

International Journal of Radiation Oncology Biology Physics

Volumn 64, Issue 4, 2006, Pages 1140-1150

  Ray, Michael E ^a,j   Thames, Howard D ^b   Levy, Larry B ^b   Horwitz, Eric M ^c   Kupelian, Patrick A ^d   Martinez, Alvaro A ^e   Michalski, Jeff M ^f   Pisansky, Thomas M ^g   Shipley, William U ^h   Zelefsky, Michael J ⁱ   Zietman, Anthony L ^h   Kuban, Deborah A ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c FOX CHASE CANCER CENTER   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e WILLIAM BEAUMONT HOSPITAL   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MAYO CLINIC   (United States)

^h MASSACHUSETTS GENERAL HOSPITAL   (United States)

ⁱ MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^j UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

more..

Author keywords

External beam radiotherapy; Prostate cancer; PSA nadir

Indexed keywords

ANTIGENS; BIOCHEMISTRY; DISEASES; RADIOTHERAPY; REGRESSION ANALYSIS; TUMORS;

EXTERNAL BEAM RADIOTHERAPY; PROSTATE CANCER; PSA NADIR;

PATIENT TREATMENT;

PROSTATE SPECIFIC ANTIGEN;

ANALYSIS OF COVARIANCE; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; METASTASIS; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROSTATE CANCER; RADIATION DOSE; REGRESSION ANALYSIS; TREATMENT FAILURE; TREATMENT PLANNING;

EID: 33644559978     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2005.07.006     Document Type: Article

References (36)

1. W.U. Shipley, H.D. Thames, H.M. Sandler Radiation therapy for clinically localized prostate cancer A multi-institutional pooled analysis JAMA 281 1999 1598 1604
2. D.A. Kuban, H.D. Thames, L.B. Levy Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era Int J Radiat Oncol Biol Phys 57 2003 915 928
3. I. Aref, L. Eapen, O. Agboola The relationship between biochemical failure and time to nadir in patients treated with external beam therapy for T1-T3 prostate carcinoma Radiother Oncol 48 1998 203 207
4. S.X. Cavanaugh, P.A. Kupelian, C.D. Fuller Early prostate-specific antigen (PSA) kinetics following prostate carcinoma radiotherapy Prognostic value of a time-and-PSA threshold model Cancer 101 2004 96 105
5. F.A. Critz, A.K. Levinson, W.H. Williams Prostate-specific antigen nadir The optimum level after irradiation for prostate cancer J Clin Oncol 14 1996 2893 2900
6. F.A. Critz, A.K. Levinson, W.H. Williams The PSA nadir that indicates potential cure after radiotherapy for prostate cancer Urology 49 1997 322 326
7. F.A. Critz, K. Levinson, W.H. Williams Prostate-specific antigen nadir of 0.5 ng/mL or less defines disease freedom for surgically staged men irradiated for prostate cancer Urology 49 1997 668 672
8. F.A. Critz, A.K. Levinson, W.H. Williams Prostate specific antigen nadir achieved by men apparently cured of prostate cancer by radiotherapy J Urol 161 1999 1199 1203
9. J.M. Crook, Y.A. Bahadur, R.G. Bociek Radiotherapy for localized prostate carcinoma The correlation of pretreatment prostate specific antigen and nadir prostate specific antigen with outcome as assessed by systematic biopsy and serum prostate specific antigen Cancer 79 1997 328 336
10. J.M. Crook, E. Choan, G.A. Perry Serum prostate-specific antigen profile following radiotherapy for prostate cancer Implications for patterns of failure and definition of cure Urology 51 1998 566 572
11. K.D. DeWitt, H.M. Sandler, V. Weinberg What does postradiotherapy PSA nadir tell us about freedom from PSA failure and progression-free survival in patients with low and intermediate-risk localized prostate cancer? Urology 62 2003 492 496
12. A.L. Hanlon, H. Diratzouian, G.E. Hanks Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer Int J Radiat Oncol Biol Phys 53 2002 297 303
13. J.M. Kaminski, A.L. Hanlon, E.M. Horwitz Relationship between prostate volume, prostate-specific antigen nadir, and biochemical control Int J Radiat Oncol Biol Phys 52 2002 888 892
14. L.L. Kestin, F.A. Vicini, E.L. Ziaja Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy Cancer 86 1999 1557 1566
15. W.R. Lee, A.L. Hanlon, G.E. Hanks Prostate specific antigen nadir following external beam radiation therapy for clinically localized prostate cancer The relationship between nadir level and disease-free survival J Urol 156 1996 450 453
16. C.A. Perez, J.M. Michalski, M.A. Lockett Chemical disease-free survival in localized carcinoma of prostate treated with external beam irradiation Comparison of American Society of Therapeutic Radiology and Oncology Consensus or 1 ng/mL as endpoint Int J Radiat Oncol Biol Phys 49 2001 1287 1296
17. A. Pollack, G.K. Zagars, J.A. Antolak Prostate biopsy status and PSA nadir level as early surrogates for treatment failure Analysis of a prostate cancer randomized radiation dose escalation trial Int J Radiat Oncol Biol Phys 54 2002 677 685
18. G.K. Zagars, A. Pollack, V.S. Kavadi Prostate-specific antigen and radiation therapy for clinically localized prostate cancer Int J Radiat Oncol Biol Phys 32 1995 293 306
19. A.L. Zietman, M.K. Tibbs, K.C. Dallow Use of PSA nadir to predict subsequent biochemical outcome following external beam radiation therapy for T1-2 adenocarcinoma of the prostate Radiother Oncol 40 1996 159 162
20. C.I. Sartor, M.H. Strawderman, X.H. Lin Rate of PSA rise predicts metastatic versus local recurrence after definitive radiotherapy Int J Radiat Oncol Biol Phys 38 1997 941 947
21. F.A. Critz Time to achieve a prostate specific antigen nadir of 0.2 ng/ml after simultaneous irradiation for prostate cancer J Urol 168 2002 2434 2438
22. American Society for Therapeutic Radiology and Oncology Consensus Panel Consensus statement Guidelines for PSA following radiation therapy Int J Radiat Oncol Biol Phys 37 1997 1035 1041
23. H. Thames, D. Kuban, L. Levy Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995 Int J Radiat Oncol Biol Phys 57 2003 929 943
24. L. Breiman, J.H. Friedman, R.A. Olshen Classification and regression trees 1984 Wadsworth Belmont, CA
25. T.M. Pisansky, M.J. Kahn, D.G. Bostwick An enhanced prognostic system for clinically localized carcinoma of the prostate Cancer 79 1997 2154 2161
26. M.W. Kattan, M.J. Zelefsky, P.A. Kupelian Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer J Clin Oncol 18 2000 3352 3359
27. A.V. D'Amico, R. Whittington, S.B. Malkowicz Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer J Clin Oncol 17 1999 168 172
28. P.W. McLaughlin, H.M. Sandler, M.R. Jiroutek Prostate-specific antigen following prostate radiotherapy How low can you go? J Clin Oncol 14 1996 2889 2892
29. A. Pollack, A.L. Hanlon, E.M. Horwitz Prostate cancer radiotherapy dose response An update of the Fox Chase experience J Urol 171 2004 1132 1136
30. P.A. Kupelian, J.C. Buchsbaum, C.A. Reddy Radiation dose response in patients with favorable localized prostate cancer (Stage T1-T2, biopsy Gleason < or = 6, and pretreatment prostate-specific antigen < or = 10) Int J Radiat Oncol Biol Phys 50 2001 621 625
31. Z. Symon, K.A. Griffith, P.W. McLaughlin Dose escalation for localized prostate cancer Substantial benefit observed with 3D conformal therapy Int J Radiat Oncol Biol Phys 57 2003 384 390
32. M.J. Zelefsky, Z. Fuks, M. Hunt High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer J Urol 166 2001 876 881
33. R. Cheung, S.L. Tucker, L. Dong Dose-response for biochemical control among high-risk prostate cancer patients after external beam radiotherapy Int J Radiat Oncol Biol Phys 56 2003 1234 1240
34. A. Pollack, L.G. Smith, A.C. von Eschenbach External beam radiotherapy dose response characteristics of 1127 men with prostate cancer treated in the PSA era Int J Radiat Oncol Biol Phys 48 2000 507 512
35. A. Pollack, G.K. Zagars, L.G. Smith Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer J Clin Oncol 18 2000 3904 3911
36. A.L. Zietman, M. DeSilvio, J.D. Slater A randomized trial comparing conventional dose (70.2 GyE) and high-dose (79.2 GyE) conformal radiation in early stage adenocarcinoma of the prostate Results of an interim analysis of PROG 95-09 [Abstract] Int J Radiat Oncol Biol Phys 60 2004 S131 S132